Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.

Article Details

Citation

Stahl SM

Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.

CNS Spectr. 2014 Dec;19(6):475-8. doi: 10.1017/S1092852914000637.

PubMed ID
25422900 [ View in PubMed
]
Abstract

ISSUE: Many individuals with total blindness can develop a circadian rhythm disorder-called non-24 sleep wake syndrome-because they cannot detect light to resynchronize their sleep-wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.

DrugBank Data that Cites this Article

Drugs